Headquartered in Ft. Collins, Colorado, Macleod Pharmaceuticals, Inc. provides products for an international customer base. Macleods primary focus is on animal health, an expanding market throughout the world. The company is the exclusive marketer for INTRACELL, an all-species wound management product. The company has come a long way since it was founded by its owner, Dr. Mike Pay, in 1989. Starting out as a subsidiary of a British veterinary pharmaceutical company, it became an American based corporation in 1991 when Dr. Pay, sold the British half of the company and moved the remaining operations to Colorado. Macleod has always maintained one underlying motive: a passion for animals and a desire to address their complex health problems. Macleod Pharmaceuticals, Inc. obtained its first FDA approval in 1993 for UNIPRIM® Powder, an equine product for fighting bacterial infections. It maintains its own in-house research and production facilities as well as off-site manufacturing capabilities through approved sub-contracting facilities. Macleods current product emphasis is on UNIPRIM® Powder For Horses and INTRACELL, and has a number of animal health products in varying stages of FDA approval.
Marksans Pharma Limited is an India-based company. The Company is primarily engaged in a single segment business of manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The Company’s subsidiaries include Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (UK) Limited. The principal activity of the Company is that of being a holding company. The Company acquired the entire ordinary share capital of Hale Group Limited (Marksans Holdings Limited) on January 18, 2008. Marksans Holdings Limited owns 100% of the ordinary share capital of Bell Sons and Co. (Druggists) Limited. (Source: ARS)
Jurox is highly committed to the research and development of products in Australia. To assist in this area's growth, Jurox commits 12% of annual sales revenue towards research and development and maintains a supporting staff of 4 veterinarians. Our Research and Development Department is both ethical and of the highest standards.
WATER-JEL® Technologies provides Emergency Medical Services, Industrial Safety professionals and the United States Military with state-of-the-art emergency first aid burn care products. We have produced such revolutionary items as WATER-JEL Fire Blankets and WATER-JEL Sterile Burn Dressings, as well as topical gels such as Burn Jel®, Cool Jel and UnBurn®. WATER-JEL has become the name to trust when it comes to emergency first aid burn care. In addition to our burn care line, our product line has been expanded to include a comprehensive selection of Emergency Burn Kits, WATER-JEL Antibiotic and Antiseptic Creams & Ointments, Non-aerosol Antiseptic Sprays, Hand Sanitizer, WATER-JEL SURE STICK® Industrial Strength Adhesive Bandages & KIDZ HEALTHÔ Children's Adhesive Bandages. Leading the industry takes more than drive and dedication. Our management team has invested heavily in state-of-the-art machinery and enterprise wide software for all of our manufacturing plants. We have also expanded distribution facilities and added new capacity for the production of private label and branded bandages. All WATER-JEL products are FDA-regulated and approved; they are manufactured in our ISO -13485 certified facility in <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />Carlstadt, New Jersey. We are lucky to be in a business where we can make a difference-- our products help people. At WATER-JEL, we are committed to continuing product development to meet the needs of our customers and to excel at our goal of Healthcare Beyond Burn Care.
http://www.novabiogenetics.com
We look to become recognized as the leading antimicrobial company in the world. We shall achieve this aim through remaining at the forefront of research and new product development, by extending and strengthening our networks and alliances, and through the provision of exceptional customer support in a growing number of diverse markets worldwide. Drawing upon our expertise and technologies, we shall at the same time continue to meet our ongoing commitment to the environment.
NecLife is a fully integrated pharmaceutical company with the capability to provide its customers with the full range of development and manufacturing services required to get their products through clinical development and into commercial production. The services offered fall into three main categories which include process development services, bulk product (API) manufacturing and finished product manufacturing. NecLife has experience with a variety of experience with High end Cephalosproin products. The services offered by NecLife include: Formulation development Lyophilization cycle development cGMP manufacturing including formulation, filling and lyophilization labeling and packaging QC testing Stability studies Regulatory support NecLife has developed a successful track record in the contract research and manufacturing industry by combining its first class facilities with the technical expertise of its staff. NecLife provides its customers with cGMP development and manufacturing services form process development to finished dosage forms. This full range of services allows NecLife to provide one-stop shopping for its customers.
Hanford Pharmaceuticals is committed to America's food producers by offering quality veterinary products that maintain the health and quality of life of herds. Throughout the United States veterinarians and producers rely on Hanford's outstanding products to improve the productivity of their livestock. Hanford's mission is providing and maintaining superior quality veterinary products to our customers and to ensure their satisfaction. Our future has never been more resolute - our employees dedicated to one aim - providing Hanford quality veterinary products throughout the United States.
eMetagen is a drug discovery company producing new pharmaceuticals from uncultivated soil microorganisms. The company discovers new antibiotics for development with partners and licensees and also markets its Gene and Pathway Banksâ„¢ as tools for drug discovery. eMetagen antibiotics target multiply drug-resistant pathogens responsible for widespread community and in-hospital infections.
Avexa Limited is an Australia-based biotechnology company with a focus on research and development of anti-infectives. The Company is developing drugs for the treatment of infectious diseases. During the fiscal year ended June 30, 2008 (fiscal 2008), the Company was engaged in anti-infective pharmaceutical programs and projects. During fiscal 2008, Avexa initiated a Phase III development program for its lead product, apricitabine (ATC), and received positive data from the 48-week Phase IIb study for ATC. In fiscal 2008, the human immunodeficiency virus (HIV) integrase and antibacterial projects also progressed towards pre-clinical studies. In its Integrase program, the Company has developed a number of small molecules that inhibit HIV infection of cells. Avexa Limited has entered into a collaboration with TargetDrug of Shanghai to develop small molecule inhibitors of hepatitis C virus (HCV). (Source: ARS)
ConjuGon was founded in 2001 by University of Wisconsin-Madison professors Marcin Filutowicz and Richard Burgess to develop products to combat the growing epidemic of antibiotic resistance. Today, the company has a dedicated team working on products to prevent and treat bacterial infections. The company's lead product, C-1205, is used to prevent catheter-associated urinary tract infections. This technology was licensed from the Baylor College of Medicine in Houston. The company's second product, B-4474, is used to treat wound infections. This product is based on technology invented by Dr. Filutowicz. ConjuGon continues to advance these products with the goal of one day helping patients prevent and treat these killer infections.
Protez Pharmaceuticals develops new antibiotics to combat the growing problem of drug resistance, as well as agents that improve the efficacy of current antibiotics. Our focus is difficult-to-treat hospital-based infections. In the United States alone, over eight million people are hospitalized with bacterial infections each year, accounting for greater than 90 million days of therapy. Many of these infections are serious and extremely difficult to treat. Additionally, of great concern to health care professionals is the fact that life-threatening microbes have developed resistant strains that no longer respond to any of the available antibiotics. We at Protez are committed to meeting the urgent need for new antibiotics by applying our expertise in antiinfectives as well as our experience in discovering, developing and marketing pharmaceuticals.
Chemeq Limited is an Australia-based veterinary pharmaceutical company, in the business of developing, manufacturing and marketing its product, CHEMEQ polymeric anti-microbial (CHEMEQ), for the prevention and control of intestinal bacterial diseases in feedstock animals, such as pigs and poultry. The Company believes that its product, CHEMEQ, has demonstrated in vitro activity against a range of microorganisms, including gram-positive and gram-negative bacteria, bacterial spores, mycobacteria, protozoa, viruses, yeasts and fungi. In addition, it believes that CHEMEQ has the same effectiveness against multiple antibiotic resistant bacteria as non-resistant bacteria, including pathogenic strains of Escherichia coli.
Affinium is a pharmaceutical company focused on the clinical development of antibacterials. Our lead development program encompasses a potent, orally available, novel antibiotic class for the treatment of antibiotic resistant staphylococcal infections. For information, please contact: Owen Roberts, CFA, Chief Financial Officer Affinium Pharmaceuticals, Inc.
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical and Related Business segment is engaged in the development, manufacturing and sale of general pharmaceuticals and diagnostic drugs, including vitamin preparations, antipyretics and analgesics, cold and sinus medicine, digestive medicine, dermatologic preparations, test paper for glucose in urine and artificial teeth-related products. The Others segment is engaged in the leasing of real estate and the provision of logistics services. The Company has 11 subsidiaries and five associated companies. The Company acquired Sciele Pharma, Inc. on October 10, 2008.
SIGA Technologies, Inc. (SIGA) is a biotechnology company that discovers, develops and commercializes anti-infectives for serious infectious diseases. The major focus of the Company's developmental and commercialization activities is on products for use in defense against biological warfare agents, such as smallpox and arenaviruses (hemorrhagic fevers). SIGA's lead product, ST-246, is an orally administered anti-viral drug that targets the smallpox virus. The Company's anti-viral programs are designed to prevent or limit the replication of the viral pathogen. SIGA's anti-infectives programs are aimed at the problem of drug resistance. (Source: 10-K)
Aurobindo Pharma was born of a vision. Founded in 1986 by Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed set of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry. Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. Over the years, the Aurobindo Pharma has evolved into a knowledge driven company. It is R&D focused, has a multi-product portfolio with multi-country manufacturing facilities, and is becoming a marketing conglomerate across the world. Aurobindo Pharma created a name for itself in the manufacture of bulk actives, its area of core competence. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company has entered the high margin speciality generic formulations segment, with a global marketing network. The formulation business is systematically organised with a divisional structure, and has a focused team for each key international market. Aurobindo believes in gaining volume and market share in every business/segment it enters. Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo's five units for APIs and four units for formulations are designed for the regulated markets. Aurobindo is one of the most reputed sources of Active Pharmaceutical Ingredient in India.
At Micrologix, we create partnerships that are based on shared visions, values, knowledge and expertise. This sharing adds value for each partner and paves the way to developing breakthrough drugs that provide solutions for unmet patient needs. Our goal is to develop win-win relationships with every partner with whom we work. Our business model focuses on developing new products from post discovery through late-stage clinical development. From an out-licensing perspective, our primary objective is to partner Micrologix' products once we establish their efficacy in humans during late Phase II to early Phase III. Where appropriate, we also out-license or collaborate on earlier stage programs. When in-licensing, we look for innovations in technology and products to fill our pipeline. We add value by applying our expertise to efficiently advance preclinical and clinical development. We offer our partners: A highly experienced senior management team with a flexible approach to collaborations A proven track record in product development and regulatory affairs A win-win partnering philosophy A corporate culture that values ethics, respect, honesty, integrity and trust A commitment to people, relationships and open communication Contact our Business Development Team: Our Business Development Team welcomes inquiries from potential licensees for Micrologix' drug candidates and programs, and from organizations with products and technologies that fit Micrologix' areas of interest and specific partnering needs.
Hovione is an international group dedicated to the cGMP development and manufacture of APIs, serving exclusively the pharmaceutical industry. With FDA inspected plants in Europe, the Far East and the US, Hovione is committed to the highest levels of service and quality. With a 50-year track record, Hovione offers advanced technologies as well as APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. Specializing in complex chemistry and particle engineering, Hovione offers all services related to the development, manufacture and pre-formulation of both new chemical entities (NCEs) and existing APIs for off-patent products. Our aim is to do well what is difficult, to give our customers what they can not find elsewhere. Aiming to provide superior customer service, we take full responsibility for all matters relating to the API from pre-IND to NDA and beyond, ensuring fast and successful product launches. Hovione's reputation as a reliable long-term supplier has been built by delivering robust solutions to our customers on time, every time. The continuity and consistency of the service we provide is based on two essential factors: focus and thoroughness. Our specialist expertise in process chemistry enables us to address the complex issues associated with the development and manufacture of APIs and regulated intermediates. Our rigorous and systematic approach to project management is complemented by experienced staff with excellent technical and practical problem-solving skills. Together, these elements guarantee an unfailing and consistent quality of end-product and service. Hovione focuses its activities on the development and production of small molecules for demanding customers in the most highly regulated markets. We have produced over 45 different APIs at a commercial scale, developed more than 100 chemical processes at industrial scale and have filings in every country that has a specific API filing requirement. With worldwide yearly revenues of about US$100m, our main markets are North America (55% of sales), Europe (25%) and Japan (12%). Hovione employs 600 people worldwide and its 3 sites have a total reactor capacity of 530m3, ranging from lab to industrial ton scale. Hovione business is 50% custom synthesis for large Pharma and Biotech companies, 50% generic products. Our latest technologies in Particle Design and our new state-of-the-art cGMP Spray Drying installation enable us to provide our customers with solutions for Advanced APIs (aAPIsÔ), a step closer in the formulation pharma process.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory